Follikuláris limfóma: vizsgálatok itt: Kína
52 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Beijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - 2/3. fázisTaking peopleA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 960 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00 - 1/2. fázisTaking peopleTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Qingdao, Shanghai, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Zhengzhou
- Életkor
- 18 év and over
- People
- 146
- Run by
- BeOne Medicines
See details and how to joinNCT05294731 - 3. fázisTaking peopleA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Nanning, Shandong, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Zhengzhou
- Életkor
- 18 év to 130 év
- People
- 1018 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Changsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 1. fázisTaking peopleA Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT07424833 - 2. fázisTaking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Beijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Hangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - 1. fázisTaking peopleClinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 18
- Run by
- Shanghai Exuma Biotechnology Ltd.
See details and how to joinNCT06830031 - 1/2. fázisTaking peopleA Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 70
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07788118 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 93
- Run by
- Sinocelltech Ltd.
See details and how to joinNCT07562022 - 1/2. fázisTaking peopleA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 92
- Run by
- Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609862 - 3. fázisNot yet taking people in KínaA Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 652
- Run by
- Ruijin Hospital
See details and how to joinNCT07719855 - 2. fázisTaking peopleCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 30
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06471738 - 2. fázisTaking peopleMosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 80
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07555470 - No phaseNot yet taking people in KínaPomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 30
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07609446 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Where
- Beijing, Changchun, Changsha, Fuzhou Fujian, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Kunming, Nanchang, Shanghai, Shenyang, Sichuan, Suzhou, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00 - 2. fázisNot yet taking people in KínaA Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
- Where
- Jinan, Nanchang, Shenzhen, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 27
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07585747 - 2. fázisTaking peopleCD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
- Where
- Beijing
- Életkor
- 18 év to 85 év
- People
- 20
- Run by
- Liping Dou
See details and how to joinNCT07587840 - 2. fázisTaking peopleZanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
- Where
- Tianjin
- Életkor
- 18 év to 90 év
- People
- 34
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07299149 - 2. fázisTaking peopleCD70-targeted immunoPET Imaging of Malignant Cancers
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 300
- Run by
- RenJi Hospital
See details and how to joinNCT06852638 - 2. fázisNot yet taking people in KínaSonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 52
- Run by
- Sun Yat-sen University
See details and how to joinNCT07550855 - 2. fázisTaking peopleOrelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 32
- Run by
- Sun Yat-sen University
See details and how to joinNCT04989621 - Korai 1. fázisTaking peopleA Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07548697